• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用干尿斑的超高效液相色谱-串联质谱法对鞘脂贮积症进行高风险筛查。

UPLC-MS/MS High-Risk Screening for Sphingolipidoses Using Dried Urine Spots.

作者信息

Martineau Tristan, Maranda Bruno, Auray-Blais Christiane

机构信息

Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Centre de Recherche-CHUS, 3001, 12th Avenue North, Sherbrooke, QC J1H 5N4, Canada.

出版信息

Biomolecules. 2024 Dec 17;14(12):1612. doi: 10.3390/biom14121612.

DOI:10.3390/biom14121612
PMID:39766319
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11727146/
Abstract

BACKGROUND

Early detection of sphingolipidoses is crucial to prevent irreversible complications and improve patient outcomes. The use of urine samples dried on filter paper (DUS) is a non-invasive strategy that simplifies the collection, storage, and shipping of samples compared to using liquid urine specimens.

OBJECTIVES

(1) Develop and validate a multiplex ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methodology using DUS to quantify twenty-one lysosphingolipids normalized to creatinine for eight different sphingolipidoses. (2) Establish normal reference values to evaluate the clinical utility of the methodology.

METHODS

Samples were eluted from a 5 cm filter paper disk (~1 mL of urine) and extracted on Oasis MCX solid-phase extraction cartridges prior to injection in the UPLC-MS/MS system.

RESULTS

Urinary lysosphingolipids were stable on DUS at -80 °C and -30 °C for 117 days, at 21.5 °C and 4 °C for at least 26 days, and at 35 °C for 3 days. Globotriaosylsphingosine, glucosylsphingosine, and their analogs were elevated in patients with Fabry disease and Gaucher disease, respectively, compared to controls (-value < 0.0001). The analysis of related analog profiles suggests a better overall reliability in detecting patients early, especially for Fabry patients.

CONCLUSIONS

This approach is feasible and might be useful for the early detection, monitoring, and follow-up of patients with sphingolipidoses.

摘要

背景

早期发现鞘脂贮积症对于预防不可逆并发症和改善患者预后至关重要。与使用液态尿液样本相比,使用滤纸上干燥的尿液样本(DUS)是一种非侵入性策略,可简化样本的采集、储存和运输。

目的

(1)开发并验证一种使用DUS的多重超高效液相色谱 - 串联质谱(UPLC-MS/MS)方法,以定量针对八种不同鞘脂贮积症的二十一种溶血鞘脂,并以肌酐进行标准化。(2)建立正常参考值以评估该方法的临床实用性。

方法

从5厘米滤纸片(约1毫升尿液)上洗脱样本,并在注入UPLC-MS/MS系统之前在Oasis MCX固相萃取柱上进行萃取。

结果

尿液溶血鞘脂在DUS上于-80°C和-30°C下可稳定保存117天,在21.5°C和4°C下至少可稳定保存26天,在35°C下可稳定保存3天。与对照组相比,法布里病和戈谢病患者的球三糖基鞘氨醇、葡萄糖基鞘氨醇及其类似物分别升高(P值<0.0001)。相关类似物谱分析表明,在早期检测患者方面,尤其是法布里病患者,整体可靠性更高。

结论

这种方法是可行的,可能有助于鞘脂贮积症患者的早期检测、监测和随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/13aae19113f9/biomolecules-14-01612-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/74d8be507dbf/biomolecules-14-01612-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/0d5443beedaf/biomolecules-14-01612-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/ac94a1723a4c/biomolecules-14-01612-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/fe458dfb6cf7/biomolecules-14-01612-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/17f33d7bb1d4/biomolecules-14-01612-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/bef907156343/biomolecules-14-01612-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/9119d15c9627/biomolecules-14-01612-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/23f1859c5547/biomolecules-14-01612-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/13aae19113f9/biomolecules-14-01612-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/74d8be507dbf/biomolecules-14-01612-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/0d5443beedaf/biomolecules-14-01612-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/ac94a1723a4c/biomolecules-14-01612-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/fe458dfb6cf7/biomolecules-14-01612-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/17f33d7bb1d4/biomolecules-14-01612-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/bef907156343/biomolecules-14-01612-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/9119d15c9627/biomolecules-14-01612-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/23f1859c5547/biomolecules-14-01612-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0375/11727146/13aae19113f9/biomolecules-14-01612-g009.jpg

相似文献

1
UPLC-MS/MS High-Risk Screening for Sphingolipidoses Using Dried Urine Spots.使用干尿斑的超高效液相色谱-串联质谱法对鞘脂贮积症进行高风险筛查。
Biomolecules. 2024 Dec 17;14(12):1612. doi: 10.3390/biom14121612.
2
Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study.血浆和干血斑溶血磷脂用于不同鞘脂贮积症的诊断:一项比较研究。
Clin Chem Lab Med. 2019 Nov 26;57(12):1863-1874. doi: 10.1515/cclm-2018-1301.
3
Lysosphingolipid urine screening test using mass spectrometry for the early detection of lysosomal storage disorders.采用质谱法进行神经鞘氨醇脂质尿液筛查试验,以早期发现溶酶体贮积症。
Bioanalysis. 2022 Mar;14(5):289-306. doi: 10.4155/bio-2021-0259. Epub 2022 Feb 4.
4
Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS.鞘脂类疾病的诊断:LC-MS/MS 同时检测溶血磷脂的新方法。
Clin Chem Lab Med. 2017 Mar 1;55(3):403-414. doi: 10.1515/cclm-2016-0340.
5
Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.采用串联质谱法对法布里病患儿进行尿生物标志物研究。
Clin Chim Acta. 2015 Jan 1;438:195-204. doi: 10.1016/j.cca.2014.08.002. Epub 2014 Aug 19.
6
Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.法布里病生物标志物:使用串联质谱法分析尿溶血型Gb3及七种相关类似物
Curr Protoc Hum Genet. 2016 Jul 1;90:17.22.1-17.22.12. doi: 10.1002/cphg.1.
7
Simultaneous quantitation of sphingoid bases by UPLC-ESI-MS/MS with identical C-encoded internal standards.采用具有相同 C 编码内标的超高效液相色谱-电喷雾串联质谱法同时定量测定鞘氨醇碱。
Clin Chim Acta. 2017 Mar;466:178-184. doi: 10.1016/j.cca.2017.01.014. Epub 2017 Jan 13.
8
LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease.血浆和羊水中间鞘脂的液相色谱-串联质谱多重分析:一种用于筛查鞘脂贮积症和尼曼-匹克C型病的新工具。
PLoS One. 2017 Jul 27;12(7):e0181700. doi: 10.1371/journal.pone.0181700. eCollection 2017.
9
High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb Isoforms Using Tandem Mass Spectrometry.法布里病的高危筛查:使用串联质谱法分析15种尿甲基化和非甲基化Gb异构体
Curr Protoc Hum Genet. 2016 Oct 11;91:17.24.1-17.24.11. doi: 10.1002/cphg.24.
10
Lysosphingolipid Quantitation in Plasma and Dried-Blood Spots Using Targeted High-Resolution Mass Spectrometry.使用靶向高分辨率质谱法定量检测血浆和干血斑中的溶血鞘脂类物质。
J Clin Lab Anal. 2025 Jan;39(1):e25131. doi: 10.1002/jcla.25131. Epub 2024 Dec 27.

本文引用的文献

1
Clinician and parent views on urine collection in precontinent children in the UK: a qualitative interview study.英国临床医生和家长对非遗尿儿童尿液采集的看法:一项定性访谈研究。
BMJ Open. 2024 Apr 29;14(4):e081306. doi: 10.1136/bmjopen-2023-081306.
2
Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States.美国异染性脑白质营养不良监测与管理的共识指南
Cytotherapy. 2024 Jul;26(7):739-748. doi: 10.1016/j.jcyt.2024.03.487. Epub 2024 Apr 1.
3
Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy.
新生儿溶酶体贮积症筛查中的光明与阴影:意大利东北部八年经验
Int J Neonatal Screen. 2023 Dec 25;10(1):3. doi: 10.3390/ijns10010003.
4
Development of a kit for urine collection on filter paper as an alternative for Pompe disease screening and monitoring by LC-HRMS.开发一种用于滤纸尿液收集的试剂盒,作为 LC-HRMS 进行庞贝病筛查和监测的替代方法。
Anal Methods. 2023 Aug 17;15(32):3932-3939. doi: 10.1039/d3ay00587a.
5
New Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases.新型干燥血斑生物标志物在溶酶体贮积症中的应用。
Int J Mol Sci. 2023 Jun 15;24(12):10177. doi: 10.3390/ijms241210177.
6
Newborn Screening for Fabry Disease: Current Status of Knowledge.法布里病的新生儿筛查:知识现状
Int J Neonatal Screen. 2023 Jun 5;9(2):31. doi: 10.3390/ijns9020031.
7
Treatment of Fabry Disease: Established and Emerging Therapies.法布里病的治疗:既定疗法与新兴疗法
Pharmaceuticals (Basel). 2023 Feb 20;16(2):320. doi: 10.3390/ph16020320.
8
An expert consensus on the recommendations for the use of biomarkers in Fabry disease.《关于应用生物标志物检测法治疗 Fabry 病的专家共识》
Mol Genet Metab. 2023 Jun;139(2):107585. doi: 10.1016/j.ymgme.2023.107585. Epub 2023 Apr 17.
9
Fabry Disease and Its Management: A Literature Analysis.法布里病及其管理:文献分析
Cureus. 2023 Apr 2;15(4):e37048. doi: 10.7759/cureus.37048. eCollection 2023 Apr.
10
The Next Frontier of Remote Patient Monitoring: Hospital at Home.远程患者监护的下一个前沿:家庭医院。
J Med Internet Res. 2023 Mar 16;25:e42335. doi: 10.2196/42335.